Albany Molecular Research, Inc. (NASDAQ:AMRI) has been upgraded by TheStreet Ratings from hold to buy. Albany Molecular Research, Inc. (NASDAQ:AMRI) shares after opening at $18.88 moved to $19.55 on last trade day and at the end of the day closed at $19.55. Company price to sales ratio in past twelve months was calculated as 2.54 and price to cash ratio as 15.80. Albany Molecular Research, Inc. (NASDAQ:AMRI) showed a positive weekly performance of 25.24%.
IGI Laboratories, Inc. (NYSEMKT:IG), a New Jersey based generic topical pharmaceutical company, announced it has received its first approval from the U.S. Food and Drug Administration (FDA) for an abbreviated new drug application (ANDA). The FDA has approved IGI’s application for lidocaine hydrochloride USP 4% topical solution. IGI Laboratories, Inc. (NYSEMKT:IG) shares advanced 9.96% in last trading session and ended the day on $5.85. IG return on equity ratio is recorded as -45.20% and its return on assets is -18.50%. IGI Laboratories, Inc. (NYSEMKT:IG) yearly performance is 265.62%.
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA based molecular diagnostics has shared detailed plans about its product pipeline based on its proprietary technology in a news release. Rosetta Genomics Ltd. (USA) (NASDAQ:ROSG) shares moved up 2.09% in last trading session and was closed at $6.35 while trading in range of $6.14 -$6.48 – Rosetta Genomics Ltd. (USA) (NASDAQ:ROSG) year to date (YTD) performance is 117.47%.
MEI Pharma Inc. (NASDAQ:MEIP) has moved higher as of late, but there could definitely be trouble on the horizon for this company. That is because MEIP is now in overbought territory with an RSI value of 70.9. Furthermore, MEI Pharma currently has a Zacks Rank #4 (Sell), suggesting that investors may want to consider exiting this stock now before it falls back to Earth. MEI Pharma Inc (NASDAQ:MEIP) weekly performance is 11.82%. On last trading day company shares ended up $11.45. MEI Pharma Inc (NASDAQ:MEIP) distance from 50-day simple moving average (SMA50) is 31.20%. Analysts mean target price for the company is $15.75.